RN Tools
Type of RCC*
Age at surgery, years*
ECOG status*
Constitutional symptoms*
Adrenalectomy*
Surgical margins*
Tumor grade*
Coagulative necrosis*
Sarcomatid differentiation*
Tumor size, cm*
Perinephric/renal sinus fat invasion*
Tumor thrombus*
Extension beyond kidney*
Nodal involvement*
Fill out the fields above to see your result.
Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC).
Scoring of features for clear cell RCC (ccRCC) is as follows:
|
Variable |
Progression-Free Survival |
Cancer-Specific Survival |
|
Age at surgery, years |
||
|
<60 |
- |
0 |
|
≥60 |
- |
1 |
|
|
||
|
0 |
- |
0 |
|
≥1 |
- |
2 |
|
Constitutional symptoms |
||
|
No |
0 |
0 |
|
Yes |
1 |
1 |
|
Adrenalectomy |
||
|
No |
- |
0 |
|
Yes |
- |
1 |
|
Surgical margins |
||
|
Negative |
- |
0 |
|
Positive |
- |
1 |
|
Tumor grade |
||
|
1 |
0 |
0 |
|
2 |
2 |
2 |
|
3 |
3 |
3 |
|
4 |
3 |
4 |
|
Coagulative necrosis |
||
|
No |
0 |
0 |
|
Yes |
2 |
2 |
|
Sarcomatid differentiation |
||
|
No |
0 |
0 |
|
Yes |
2 |
3 |
|
Tumor size, cm |
||
|
≤4 |
0 |
0 |
|
>4 to ≤7 |
3 |
4 |
|
>7 to ≤10 |
4 |
4 |
|
>10 |
4 |
5 |
|
Perinephric/renal sinus fat invasion |
||
|
No |
0 |
0 |
|
Yes |
1 |
2 |
|
Tumor thrombus* |
||
|
No |
0 |
0 |
|
Level 0 |
1 |
0 |
|
Level 1-4 |
2 |
1 |
|
Extension beyond kidney |
||
|
No |
0 |
- |
|
Yes |
2 |
- |
|
Nodal involvement |
||
|
No nodal dissection |
0 |
0 |
|
No |
0 |
0 |
|
Yes |
2 |
2 |
*Tumor thrombus level was defined by the Neves and Zincke classification.
Scoring of features for papillary RCC (papRCC) is as follows:
|
Risk Group |
Features |
|
Group 1 |
|
|
Group 2 |
|
|
Group 3 |
or
or
|
Scoring of features for chromophobe RCC (chrRCC) is as follows:
|
Risk Group |
Features |
|
Group 1 |
|
|
Group 2 |
|
|
Group 3 |
or
and/or
|
Interpretation:
|
Progression-Free Survival |
|||
|
5 Year |
10 Year |
15 Year |
|
|
ccRCC Score |
|||
|
0 |
98% |
97% |
96% |
|
1 |
97% |
95% |
94% |
|
2 |
95% |
93% |
92% |
|
3 |
93% |
91% |
89% |
|
4 |
91% |
87% |
84% |
|
5 |
87% |
82% |
79% |
|
6 |
82% |
76% |
71% |
|
7 |
75% |
67% |
61% |
|
8 |
66% |
57% |
50% |
|
9 |
56% |
45% |
37% |
|
10 |
44% |
32% |
24% |
|
11 |
31% |
20% |
13% |
|
12 |
19% |
10% |
6% |
|
13 |
9% |
4% |
2% |
|
14 |
3% |
1% |
<1% |
|
≥15 |
1% |
<1% |
<1% |
|
papRCC Risk Group |
|||
|
1 |
97% |
97% |
96% |
|
2 |
89% |
86% |
84% |
|
3 |
60% |
52% |
46% |
|
chrRCC Risk Group |
|||
|
1 |
94% |
91% |
89% |
|
2 |
71% |
59% |
51% |
|
3 |
13% |
4% |
2% |
|
Cancer-Specific Survival |
|||
|
5 Year |
10 Year |
15 Year |
|
|
ccRCC Score |
|||
|
0 |
99% |
99% |
98% |
|
1 |
99% |
98% |
98% |
|
2 |
99% |
98% |
97% |
|
3 |
98% |
97% |
96% |
|
4 |
97% |
95% |
94% |
|
5 |
96% |
94% |
92% |
|
6 |
95% |
92% |
89% |
|
7 |
93% |
89% |
86% |
|
8 |
90% |
85% |
81% |
|
9 |
87% |
80% |
75% |
|
10 |
83% |
74% |
68% |
|
11 |
77% |
66% |
59% |
|
12 |
70% |
57% |
49% |
|
13 |
62% |
47% |
37% |
|
14 |
52% |
35% |
26% |
|
15 |
41% |
24% |
16% |
|
16 |
29% |
14% |
8% |
|
17 |
19% |
7% |
3% |
|
≥18 |
10% |
3% |
1% |
|
papRCC Risk Group |
|||
|
1 |
99% |
98% |
98% |
|
2 |
95% |
91% |
90% |
|
3 |
74% |
60% |
56% |
|
chrRCC Risk Group |
|||
|
1 |
96% |
95% |
94% |
|
2 |
85% |
79% |
76% |
|
3 |
49% |
34% |
30% |
Apply after partial or radical nephrectomy for localized or locally‑advanced, non‑metastatic renal cell carcinoma (RCC) once final pathology is available, to stratify risk for progression and death.